RxDoctor Payments Data

Steven Resnick, DO

Neurology · Bay Harbor Islands, FLNPI 1972553816

Payments from drug & device makers

$9,024in general payments, 2019–2025

Across 490 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Pfizer$700
  • AstraZeneca$510
  • GE HealthCare$478
  • Biohaven Pharmaceutical Holding Company Ltd.$463
  • Teva Pharmaceuticals USA, Inc.$442
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$8,85198%
  • Education$1732%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,024 in reported general payments places this provider in the 65th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$466,800
Medicare patients
584
Services billed
27,354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab18$168,872
OctagamImmun Globg(Igg)/Malt/Iga Ov5026$124,294
Avonex (4 Pack)Interferon Beta-1a12$99,098
AustedoDeutetrabenazine12$89,722
Nurtec OdtRimegepant Sulfate53$74,918
Emgality PenGalcanezumab-Gnlm69$56,769
Aimovig AutoinjectorErenumab-Aooe25$34,568
QuliptaAtogepant21$23,165
VimpatLacosamide17$21,561
LamictalLamotrigine13$16,973
Keppra XrLevetiracetam12$16,427
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone24$7,707
Gabapentin206$6,499
AmantadineAmantadine Hcl76$5,778
Carbidopa-LevodopaCarbidopa/Levodopa271$3,887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt$700$199,21279 claims
BiogenAvonex (4 Pack)$76$99,09812 claims
Teva Pharmaceuticals USA, Inc.Austedo$442$89,72212 claims
AbbVieQulipta$2,705$23,16521 claims
UCB, Inc.Vimpat$250$21,56117 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$114$1,72029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,434 neurology providers in Florida.

Other neurology in Bay Harbor Islands

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →